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Purification of 11b-hydroxysteroid dehydrogenase type 2 from human
placenta utilizing a novel affinity labelling technique
Roger W. BROWN*, Karen E. CHAPMAN, Parvez MURAD, Christopher R. W. EDWARDS and Jonathan R. SECKL
University Department of Medicine, Western General Hospital, Edinburgh EH4 2XU, Scotland, U.K.
11b-Hydroxysteroid dehydrogenase type 2 (11b-HSD2) effic-
iently inactivates potent glucocorticoid hormones (cortisol and
corticosterone), leaving aldosterone unmetabolized. Abundant
11b-HSD2 activity in human placenta plays a central role in
controlling fetal glucocorticoid exposure, which if excessive is
harmful and may predispose to low birth weight and hypertension
in adulthood. Similar 11b-HSD2 activity in the distal nephron
protects mineralocorticoid receptors from glucocorticoids and
appears to be important in normal blood pressure control.
We have purified human placental 11b-HSD2 16000-fold, to
homogeneity, and determined over 100 residues of the internal
amino acid sequence. Purification was assisted by a novel
INTRODUCTION
11b-Hydroxysteroid dehydrogenase (11b-HSD) catalyses the
rapid metabolism of physiological glucocorticoids (cortisol and
corticosterone) to inactive 11-dehydro products (cortisone and
11-dehydrocorticosterone respectively). In any tissue the activity
of 11b-HSD will affect the amount of circulating glucocorticoids
reaching their intracellular receptors [glucocorticoid receptors
(GR) and mineralocorticoid receptors (MR)]. Moreover, as the
mineralocorticoid aldosterone is not metabolized by 11b-HSD, it
can gain selective access to the MR in the face of 100–1000-fold
higher levels of circulating glucocorticoids, providing that 11b-
HSD activity is sufficient to eradicate the glucocorticoid. It is
now widely believed that just such a selective barrier to gluco-
corticoid is present in aldosterone target tissues [1,2] (e.g. the
distal nephron in kidney) and enables potent effects on fluid and
electrolyte balance and blood pressure to be exerted by aldo-
sterone acting through MR (which in itro bind aldosterone and
physiological glucocorticoids with equal affinity [3]). Deficiency
of 11b-HSD due either to the congenital syndrome of apparent
mineralocorticoid excess (SAME) [4,5] or to the ingestion of 11b-
HSD inhibitors [6] (liquorice constituents or carbenoxolone)
leads to the normally protected tissues being accessed by gluco-
corticoids, which occupy MR and cause mineralocorticoid
hypertension.
There is also abundant 11b-HSD activity in the placenta which
has a major influence on the glucocorticoid exposure of the
developing fetus [7–10]. Glucocorticoids are important in normal
development, facilitating the maturation of tissues (e.g. lung [11])
and influencing the set point of aspects of fetal physiology, a
number of which then become fixed for life (fetal programming)
[12–15]. If the fetus is exposed to excessive glucocorticoids, birth
weight is reduced [9,16] and, in animal models, the offspring are
hypertensive in adulthood [9]. Inhibition of placental 11b-HSD
Abbreviations used: 11b-HSD(2), 11b-hydroxysteroid dehydrogenase (type 2) ; GR, glucocorticoid receptors ; MR, mineralocorticoid receptors ; SAME,
syndrome of apparent mineralocorticoid excess ; CAPS, 3-(cyclohexylamino)-1-propanesulphonic acid ; 2-D, two-dimensional ; CMC, critical micelle
concentration; IEF, isoelectric focusing; NEPHGE, non-equilibrium pH-gradient gel electrophoresis ; TFA, trifluoroacetic acid ; SCAD, short-chain
alcohol dehydrogenase; PVDF, poly(vinylidene difluoride).
* To whom correspondence should be addressed.
technique allowing highly specific (single spot on two-
dimensional electrophoresis) photoaffinity labelling of active
11b-HSD2 in crude tissue extracts by its glucocorticoid sub-
strates. This work reveals that 11b-HSD2 is a member of the
short-chain alcohol dehydrogenase superfamily (apparent mon-
omer M
r
C 40000). It is a very basic (apparent pI¯ 9.1)
intrinsic membrane protein, requiring as yet undefined membrane
constituents for full stability. Affinity chromatography and
affinity labelling studies suggest that 11b-HSD2 has a compulsory
ordered mechanism, with NAD+ binding first, followed by a
conformational change allowing glucocorticoid binding with
high affinity.
similarly reduces birth weight and results in hypertensive off-
spring (R. S. Lindsay, R. M. Lindsay, C. R. W. Edwards and
J. R. Seckl, unpublished work). Human epidemiology also reveals
that those babies with the lowest birth weight have the greatest
risk of adult hypertension [17]. Furthermore, in rats [9] and
humans [10], birth weight correlates with placental 11b-HSD
activity.
The previously identified isoform of 11b-HSD (11b-HSD1) is
not responsible for the renal and placental barriers to gluco-
corticoids. It has been purified from rat liver [18], and cor-
responding rat [19], human [20], squirrel monkey [21], sheep [22]
and mouse [23,24] cDNA clones have been isolated. 11b-HSD1
is a reversible, NADP(H)-dependent enzyme, with high ex-
pression in some tissues (e.g. liver), but not in the distal nephron
or placenta, and it has relatively low affinity for glucocorticoids
(K
m
in the low micomolar region) [18]. Moreover, no mutations
of the 11b-HSD1 gene have been identified in SAME patients
[25]. A distinct NAD+-dependent, exclusively dehydrogenase,
11b-HSD activity with high affinity for glucocorticoids has been
identified in biochemical studies in rabbit kidney cortical collec-
ting duct cells [26] and human placenta [27]. Similar activity has
now been described in renal tissue of other species [28] and
several human fetal tissues [29]. These activities are due to a
distinct isoform, 11b-HSD2 (or possibly several closely related
ones), and seem likely to be responsible for the important
barriers to glucocorticoid access described above. Further study
of 11b-HSD2 has been hampered by the lack of specific ‘mole-
cular tools ’ to investigate it at the protein and nucleic acid levels.
In this paper we present the first purification of 11b-HSD2 to
homogeneity and an extensive amino acid sequence derived
directly therefrom. We also describe a novel affinity labelling
procedure allowing 11b-HSD2 to be specifically labelled by its
natural substrates. Aspects of this work should facilitate study of
the mechanism of action of 11b-HSD2 and the mapping of its
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active site. Such studywill be valuable in the efficient design of new
drugs influencing corticosteroid physiology (e.g. by selectively
inhibiting, bypassing or being metabolized effectively by this key
enzyme). In an accompanying paper we report use of the 11b-
HSD2 amino acid sequence to isolate and characterize a full-
length human placental 11b-HSD2 cDNA clone and to raise
antisera to the placental 11b-HSD2 protein [30].
EXPERIMENTAL
Materials
[1,2,6,7-$H]Corticosterone, [1,2,6,7-$H]cortisol, [1,2,4,6,7-$H]
dexamethasone and [1,2,6,7-$H]aldosterone (specific radio-
activity 78, 73, 84 and 80 Ci}mmol respectively) were obtained
from Amersham International (Little Chalfont, Bucks., U.K.).
Autodigestion-resistant modified trypsin and Staphylococcus
aureus V8 protease were obtained from Promega (Southampton,
U.K.), and hydrogenated Triton X-100 (RTX-100; protein grade)
was from Calbiochem (Nottingham, U.K.). Glycerol and protein
standards for SDS}PAGE (g44264L), electrophoresis-grade SDS
and urea were purchased from BDH Laboratory Supplies (Poole,
Dorset, U.K.). Coomassie Blue dye concentrate, standardized
BSA and protein standards for two-dimensional (2-D) electro-
phoresis (g1610320) were purchased from Bio-Rad (Hemel
Hempstead, U.K.). HPLC-grade methanol and water were
purchased from Rathburn Chemicals (Walkerburn, Scotland,
U.K.) and Quickszint 302 HPLC scintillant was from Zinsser
Analytic (Maidenhead, U.K.). Entensify fluoroautoradiography
solutions were obtained from du Pont}NEN (Stevenage, U.K.).
Poly(vinylidene difluoride) (PVDF; Problott) membranes were
obtained from Applied Biosystems (Warrington, U.K.). Affinity
chromatography matrices, Pharmalytes, detergents and other
chemicals were obtained from Sigma Chemical Co. (Poole,
Dorset, U.K.).
Buffers
Chromatography buffer systems used were as follows. Buffer A:
20% glycerol, 5 mM potassium phosphate, pH 7.0, 1 mM
EDTA, 1 mM dithiothreitol. Buffer B: 10% glycerol, 300 mM
NaCl, 4 mM CHAPS, 1 mM EDTA, 0.02M Tris}HCl, pH 7.7.
Buffer C: 10% glycerol, 300 mM NaCl, 1 mM EDTA, 0.02 M
Tris}HCl, pH 7.7. Where the buffer varies from that above, the
variation is appended in [brackets].
Subcellular fractionation of placental tissue
Human term placentae (400–600 g; normal vaginal delivery)
were rapidly placed on ice, and tissue was processed within 2 h.
Adherent membranes, umbilical cord and large vessels were
removed. Placental tissues were rapidly minced with scissors,
washed in ice-cold 0.9% NaCl, blotted dry, suspended in
approximately 3 times their weight of buffer A and homogenized
with a commercial blender. Homogenate was filtered through
two layers of muslin and the filtrate fractionated rapidly by
differential centrifugation: (i) 10 min at 750 g, (ii) 40 min at
25000 g and (iii) 60 min at 110000 g. The supernatant from each
centrifugation was subjected to the next centrifugation, finally
leaving a cytosolic supernatant. Resulting fractions were frozen
at ®80 °C or used immediately.
Assays of 11b-HSD activity
11b-HSD2 activity was determined by measuring the percentage
conversionof1.12¬10−) M $H-labelled steroid substrate (cortico-
sterone unless otherwise stated) to product (11-dehydrocortico-
sterone) in the presence of NAD+ (400 lM unless otherwise
stated). The 250 ll assay consisted of 10 ll containing tritiated
steroid, 50 ll containing cofactor and 190 ll of enzyme in buffer
C. Reactions were incubated at 37 °C for 10 min and terminated
by adding 2 ml of ethyl acetate. The steroids (in the organic
layer) were assayed by HPLC as previously described [27], and
the percentage conversion of steroid substrate to product was
calculated as an index of enzyme activity. Protein was estimated
by the method of Bradford [31]. 11b-HSD assay conditions were
such that the amount of protein added was in the linear region
of the curve of protein concentration versus percentage substrate
converted with 400 lM NAD+, and resulted in conversion of
10–40% in 10 min. All experiments had blank (no protein)
assays run in parallel. Kinetic parameters were calculated from
initial-velocity determinations in assays giving less than 30%
conversion.
Detergent solubilization
All solubilization was carried out at 0–2 °C. Tissue fractions,
resuspended in buffer C to 6 mg of protein}ml, were mixed with
an equal volume of solubilization buffer (in buffer C with
detergent at twice the final concentration). After 30 min the
mixture was centrifuged at 110000 g for 1 h. Supernatant con-
taining soluble enzyme was carefully removed. A screen was
performed using 13 detergents of diverse classes [32] (Triton
DF18 [18], CHAPS, taurodeoxycholic acid, polyoxyethylene-10-
lauryl ether, digitonin, n-octyl glucoside, Tween 20, Tween 80,
SDS, n-lauryl sarcosine, Triton X-100, Zwittergent 3-10 and
Bigchap). Following this screen, conditions were refined for the
most promising detergent (CHAPS).
Affinity chromatography
Affinity chromatography matrices were hydrated, loaded into
simple columns and equilibrated in buffer B. For the preparative
5«-AMP–agarose chromatography, six 5 ml columns were run in
parallel, having a common outflow; 5 ml fractions were collected.
A CHAPS-solubilized placental 25000 g pellet fraction (180 ml)
was loaded (2.4 ml}min) on to the columns, which were then
washed with 205 ml of buffer B and 45 ml of buffer B[0.25 M
NaCl], and 11b-HSD was eluted with 170 ml of buffer B[0.2 M
NaCl­1 mM NAD+], all at 3.5 ml}min. Fractions were placed
on ice and rapidly assayed for 11b-HSD enzyme activity.
Fractions with abundant 11b-HSD2 were pooled and con-
centrated (Amicon stirred cells ; Centricon 10 concentrators ;
acetone precipitation).
Analytical work used 1 ml columns run manually (1.0–1.5 ml
fractions). To obtain the highest purity of eluted 11b-HSD an N-
6-5«-AMP–agarose column was washed with buffer B (15 ml),
buffer B[0.02 M NaCl­0.4 mM NADH] (10 ml) and buffer B
(15 ml), and then eluted with buffer B[0.125 M NaCl­1 mM
NAD+]. The flow rate was 420 ll}min, decreasing to
200–300 ll}min on elution. The increased purity was at the cost
of lower yield and reproducibility than with the preparative
protocol (above).
UV photoaffinity labelling and fluoroautoradiography
A portion of 467 ll of tissue sample diluted in buffer C was
added to wells of 24-well plates (diameter 15 mm) and maintained
at 37 °C for 3 min. Addition of 60 ll of 250 mM dithiothreitol,
48 ll of 5 mM NAD+ (both in buffer C) and finally [$H]steroid
(in 25 ll of 10% ethanol}buffer C) completed the reaction,
giving approx. 50 nM [$H]steroid in 600 ll, unless otherwise
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stated. In the experiments presented here (to minimize UV
damage to protein), reactions were placed in UV light (312 nm
transilluminator at a distance of 50 mm above plate ; lid off) for
15 min at 37 °C. The procedure was easily scaled up. Similar
labelling occurs at 254 nm and is even stronger at 0 °C or with
longer UV exposure. However, all three of these variations also
induce formation of minor bands below M
r
40000, and protein
damage with prolonged 254 nm UV exposure will be more
extensive.
Labelled samples were acetone-precipitated and resolved by
SDS}PAGE [33] or 2-D electrophoresis. Finished gels, stained
with Coomassie Blue to allow detection of major proteins and
M
r
standards, were processed for fluoroautoradiography in
Entensify solutions and vacuum-dried before exposure to film.
2-D electrophoresis
2-D electrophoresis work involved running duplicate gels in
parallel ; usually one was silver stained (to visualize all the
proteins), and the other stained with Coomassie Blue (to allow
alignment between gels and to visualize SDS}PAGE protein
standards) and processed for autoradiography. A set of 2-D
electrophoresis protein standards was run under identical con-
ditions on a third gel when new running parameters were used.
Conventional 2-D PAGE, i.e. isoelectric focusing (IEF) plus
SDS}PAGE, used a variation of the method of O’Farrell [34].
2-Dnon-equilibrium pH-gradient gel electrophoresis (NEPHGE)
conditions were based on the methods of O’Farrell [35] and
Witzmann [36], with variations of sample buffer and rod gel
composition. Rod gels (170 mm¬2.5 mm; length¬internal
diameter) were cast from 9 M urea, 2% Nonidet P40, 4%
acrylamide}bisacrylamide (19:1, w}w) and 3% Pharmalytes
(1.2% pH 6–8 and 1.8% pH 3–10), and polymerized with 32 ll
of 10% ammonium persulphate and 27 ll of NNN«N«-tetra-
methylethylenediamine (TEMED) per 20 ml of rod gel mixture.
Optimal results (higher yield, better resolution), especially for
basic hydrophobic proteins, were obtained with a dodecyl
maltoside-based NEPHGE sample buffer : 5.71 g of urea, 154 mg
of dithiothreitol, 4 ml of 10% dodecyl maltoside, 750 ll of
Pharmalytes (300 ll of pH 6–8; 450 ll of pH 3–10) and 2.25 ml
of HPLC-grade water, and adjusting the pH to 4.2 (by adding
approx. 90 ll of 5 M HCl and 160 ll of HPLC-grade water).
This buffer, which was a great improvement, is close to solidifying
at room temperature and is melted, by warming to 30 °C, to
adjust pH on preparation and on use. NEPHGE gels were run at
500 V for 2250 V[h. After NEPHGE, rods were extruded into
10 ml of equilibration buffer for 7 min and either frozen or
loaded directly on to second-dimension SDS}PAGE gels. Equi-
libration buffer (150 ml) consisted of 15 ml of b-mercaptoethanol,
9 g of SDS, 90 ml of HPLC-grade water, 5.6 ml of 0.075%
Bromophenol Blue and 37.5 ml of 4¬ Laemmli stacking buffer
(0.4% SDS, 0.5 M Tris}HCl, pH 6.8). For both IEF and
NEPHGE the second dimension was run according to the
resolving gel system of Laemmli [33] using 12.5% gels (3.3%
cross-linker). Silver staining was by the method of Wray [37].
Concentrated protein from preparative AMP affinity chroma-
tography runs was divided among several 1.5 mm-thick pre-
parative 2-D gels. Precautions were taken to minimize protein
N-terminal modifications : the second-dimension gel was pre-run
in a Laemmli running buffer containing 0.5% (v}v) freshly made
100 mM glutathione and then changed to running buffer with
0.1% (v}v) 100 mM sodium thioglycholate [38]. These pre-
cautions were successful in allowing N-terminal sequence to be
obtained for other proteins in our laboratory.
Protein blotting for sequencing
This was based on the CAPS [3-(cyclohexylamino)-1-
propanesulphonic acid] buffer method of Matsudaira [39] and
was performed from SDS}PAGE or second-dimension gels on to
PVDF (Problott) membranes using a Bio-Rad Mini Trans-Blot
apparatus. Sections of gels to be blotted were washed for exactly
30 s in CAPS transfer buffer (to allow shrinkage and removal of
excess surface SDS). Electroblotting was for 75 min at 250 mA
(90–110 V). After transfer, the PVDF sheets were stained (Amido
Black), destained (water) and air dried, and desired bands}spots
were cut out and stored at ®70 °C.
Proteolytic digests of PVDF-blotted protein
These were based on the method of Fernandez et al. [40]. Mem-
branes were cut into small pieces, blocked [0.2% polyvinyl-
pyrrolidone (average M
r
40000) in methanol for 45 min] and
extensively washed in deionized HPLC-grade water.
Autodigestion-resistant trypsin was added in AHT buffer (20%
acetonitrile, 1% hydrogenated Triton X-100 in 100 mM Tris,
pH 8) to a concentration of 1:20 (w}w) (trypsin}blotted protein),
and digestion was continued for 24 h at 37 °C. Fragments were
eluted using vigorous sonication and washes [AHT buffer, then
0.1% (w}v) trifluoroacetic acid (TFA)] [40]. Eluted peptides
were concentrated, removing the acetonitrile, and loaded as a
100 ll sample on to an Applied Biosystems microbore HPLC
system fitted with a C8 RP300 column (1 mm¬250 mm; 7 lm
particle size) equilibrated in solvent A (0.1% TFA}water). This
was developed with a linear gradient of 0–100% solvent B
(0.08% TFA in 80% acetonitrile}water) over 45 min at
200 ll}min. The spectrophotometric absorbance at 220 nm (A
##!
)
of eluate allowed collection of peptide peaks. Control digests
(trypsin with polyvinylpyrrolidone-blocked blank PVDF slices)
were run in parallel to ensure identification of all peaks not due
to the blotted protein substrate. A large peptide peak yielding no
sequence which was thought to be the blocked N-terminal
peptide was sub-digested in solution (50 mM sodium phosphate,
pH 7.8) with S. aureus V8 protease at an estimated concentration
of 20:1 (w}w, peptide}protease). Products were resolved on
HPLC, as were those from a control (protease only) digest.
Amino acid sequencing
Peptide peaks selected for sequencing were pyridyl-ethylated
[41], to allow detection of cysteine residues, and loaded into an
Applied Biosystems 477A automated amino acid micro-
sequencer.
RESULTS AND DISCUSSION
Subcellular fractionation
Human placental 11b-HSD activity was well preserved during
subcellular fractionation. Placental 11b-HSD was clearly a
membrane-associated protein (as ! 2% of activity remained in
the cytosolic supernatant) and was most abundant in the 25000 g
pellet, which contained over two-thirds of the total enzyme
activity in under one-sixth of the total protein. Differential
centrifugation of the 25000 g pellet did not produce any useful
refinement. This fraction was used for further purification, and
has been found to be very stable on storage at ®70 °C, with no
decline in activity in over 2 years.
Solubilization
Solubilization (i.e. remaining in supernatant after 1 h at
110000 g) of placental 11b-HSD (from resuspended 25000 g
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(a)
(b)
Figure 1 5«-AMP affinity chromatography
(a) SDS/12.5%-PAGE gels (silver stained) from 5«-AMP–agarose chromatography. 11b-
HSD2 activity (percentage conversion of 12 nM [3H]corticosterone in 10 min) is indicated above
the lanes ; ND, not detected. The positions of 11b-HSD2 protein (starred arrow) and of markers
(10−3¬Mr) are shown between the panels. Left panel, preliminary analytical study showing
samples before, during and after harsh elution with NAD+ (fractions 31–34) ; right panel,
samples from two particularly clean analytical runs (A1 and A2) and pooled high-activity
fractions from two typical preparative runs (P1 and P2), as described in the Experimental
section. For analytical runs 190 ll samples of fractions were used in standard 11b-HSD assays
and 1 ml samples (acetone precipitated) were used for SDS/PAGE ; in preparative runs 50 ll
(assays) and 250 ll (SDS/PAGE) samples were used. (b) Chromatographic profile of
preparative-scale run showing 11b-HSD2 activity (bars) in relation to A280 (protein concentration
or NAD+ on elution) of fractions (5 ml) from the common outflow of six 5 ml AMP–agarose
columns run in parallel. Fractions 1–36, loading ; 37–86, washes ; 87–120, elution with 1 mM
NAD+. The most active of these fractions are equivalent to samples P1 and P2 described above.
pellet) was attempted using 0–2.4 M NaCl. The ionic strength
clearly affected 11b-HSD activity before centrifugation (activity
was highest with 0.3 M NaCl: 160% of that with no NaCl). As
C 99% remained insoluble, solubilization was attempted with
an extensive screen of detergents. Placental 11b-HSD activity
was inactivated by concentrations of detergents required to
transform membrane proteins fully into micelles [detergent
concentration(critical micelle concentration (CMC)] ; however,
limited though useful solubilization was achieved with gentle
(a) (b)
Figure 2 Native photoaffinity labelling of 11b-HSD2
The bottom panels are autoradiographs of labelled protein samples run on the SDS/12.5%-
PAGE gels shown in the top panels (stained with Coomassie Blue). 10−3¬Apparent Mr
of protein standards (PS) are indicated on the left side of the gels. (a) Triplicate samples of rat
liver microsomes (‘ Liver ’), AMP-chromatography-purified human placental 11b-HSD (‘Purified ’ ;
similar to fraction 32 in Figure 1) and three human placental subcellular fractions (Cytosol,
25000 g and Nuclear). All samples were photoaffinity labelled simultaneously with [3H]corti-
costerone in the presence of 400 lM NAD+ (lanes d), 400 lM NADP+ (lanes p), both
cofactors at 400 lM (lanes dp) or both cofactors plus 50 lM carbenoxolone (lanes cx). A single
protein band at 40000-Mr is labelled in an NAD+-dependent, carbenoxolone-blockable fashion.
(a) samples of human placental 25000 g pellet (mitochondria­heavy microsomes)
photoaffinity labelled simultaneously in the presence of 400 lM NAD+ and [3H]cortisol (F),
[3H]corticosterone (B) or [3H]dexamethasone (Dx). Protein loading was ! 0.5 lg for ‘ Purified ’
lanes ; otherwise it was C 30 lg/lane.
conditions (detergent concentration!CMC), being best with
zwitterionic detergents with bile acid- or steroid-like head groups.
CHAPS (4 mM) in combination with buffer C (which contains
0.3 M NaCl) was found to be optimal, solubilizing 40–45% of
the 25 000 g pellet protein and 9.5% of its 11b-HSD activity. On
repeated re-extraction of the initially insoluble protein with
4 mM CHAPS, 13–20% of the original 11b-HSD activity could
be solubilized. Thus placental 11b-HSD2 appears to be an
integral membrane protein that requires factor(s) present in
membrane subfractions of the placenta which are not satis-
factorily substituted by a wide range of detergents.
Affinity chromatography
Since 11b-HSD uses NAD+ and glucocorticoids as substrates,
columns with ligands that mimic these factors were screened. It
was found that one matrix, N-6-linked 5«-AMP–agarose (Sigma;
cat. no. A3019), bound substantial 11b-HSD activity that could
be eluted with cofactor (NAD+ "NADH" 5«-AMP(
NADP+). Two other kinds of 5«-AMP–agarose [ribose hydroxyl-
(Sigma A8895) and C-8-linked (Sigma A1271)] and two types of
NAD+–agarose were ineffective, with a small percentage (2%)
binding to the third type of NAD+–agarose available (linked at
C-8; Sigma N1008), eluting specifically with NAD+. 11b-HSD
activity did not bind to NADP+–agarose, cAMP–agarose or
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dexamethasone–agarose (Sigma D4657; 0.5–1.0 lmol}ml dexa-
methasone immobilized at C-17).
Preliminary studies with this N-6-linked 5«-AMP–agarose
revealed it to be very useful for 11b-HSD2 purification. Over a
large number of running conditions, a band migrating at approx.
M
r
40000 on SDS}PAGE was seen to co-segregate with the 11b-
HSD2 activity of the fractions (e.g. Figure 1a). Chromatography
for highest purity (e.g. lanes A1 and A2, Figure 1a) suffered from
a low yield of active 11b-HSD.
The large-scale preparative conditions adopted (see the Ex-
perimental section and Figure 1b) reproducibly gave a 20-fold
higher yield (35%) at somewhat decreased, though still 1000-
fold, purification (Figure 1a, lanes P1 and P2). The 40000-M
r
band (starred) was the most prominent, but contamination
persisted at various M
r
values, notably several narrow bands
very close to (especially above) 40000. These closely flanking
bands indicated contaminating proteins that were likely to defeat
further purification steps based solely on resolution by size (e.g.
gel filtration). Accordingly it was decided to separate by size and
charge using 2-D electrophoresis. As this would inevitably result
in inactivation of 11b-HSD2 activity, an alternative method of
detecting the enzyme was required. This was provided by a novel
affinity labelling method.
Affinity labelling
Kinetic studies of 11b-HSD2 purified by AMP–agarose chroma-
tography revealed a very low K
m
for corticosterone (14³1 nM)
[27], and therefore affinity labelling with this steroid was attem-
pted. As Figure 2 shows, a protein with all the expected
characteristics of 11b-HSD was uniquely photoaffinity labelled.
This protein was M
r
40000 in size, and was present in the
subcellular fractions along with 11b-HSD activity [25000 g pellet
750 g pellet (nuclear}debris)E110000 g pellet (light microsomes;
not shown)], but absent from cytosol. The labelling was NAD+-
dependent, independent of NADP+ and blocked by carben-
oxolone. Labelling of fractions after AMP–agarose chromato-
graphy showed the labelled protein exactly corresponded to 11b-
HSD activity, being present when 11b-HSD was eluted with
NAD+ (e.g. Figure 1b, fractions 87–120) and in the flow-through
(fractions 1–30), but absent from the inactive wash fractions.
Moreover, the same protein could be affinity labelled with
cortisol and dexamethasone (corticosterone( cortisol(dexa-
methasone; Figure 2b), but there was no labelling with aldo-
sterone. This novel technique appears to result in completely
selective labelling of placental 11b-HSD by glucocorticoids, with
a potency which parallels their affinities as substrates for the
enzyme. Using this technique it was possible to track the 11b-
HSD2 protein after activity had been lost, so allowing final
purification by 2-D electrophoresis.
The affinity labelling technique developed here is unusually
straightforward and specific for 11b-HSD2. Photoaffinity label-
ling is more commonly described for receptors and binding
proteins, and a few such procedures report labelling by un-
modified steroid compounds acting as the ligand (e.g. GR by
dexamethasone), but even in such cases these ‘common’ ligands
lack the desired specificity and are replaced by compounds
developed to allow high specificity (e.g. RU26988 and RU28362
for exchange assays}photoaffinity labelling specific for the GR
[42,43]). Affinity labelling of enzymes is much less common by
photoactivation, and is more often achieved using a specifically
designed activatable compound containing a reactive functional
group (usually electrophilic, e.g. bromoacetate) which is attacked
by an activating substituent (usually a nucleophilic side chain of
an amino acid) in the enzyme’s active site ²e.g. 3-methoxyoestriol
16-(bromo[2-"%C]acetate) labelling of homogeneous placental
17b-HSD type 1 at two histidines in its active site [44]´. Less
commonly, enzymes can be photoaffinity labelled by precisely
chosen synthetic compounds which, when photoactivated, de-
velop short-lived, highly reactive substituents which label the
target enzyme if a suitable amino acid residue is nearby (e.g. UV-
induced labelling by 19-nortestosterone acetate of purified D&-3-
ketosteroid isomerase from Pseudomonas testosteroni [45]). What
makes the labelling technique described here particularly unusual
is that it can use a physiological substrate in a crude tissue extract
containing thousands of different proteins (in contrast to the two
examples given above, which used pure enzyme), and labels the
enzyme for that substrate with such specificity that analysis
reveals only a single spot on 2-D electrophoresis. To our
knowledge, the only other study describing photoaffinity labelling
of a steroid-metabolizing enzyme by what may be a natural
substrate is the labelling of Pseudomonal D&-3-ketosteroid iso-
merase with testosterone [45]. This, however, is a less avid label
than synthetic 19-nortestosterone acetate. Though the parallels
are intriguing, that study [45] utilized pure enzyme and C 500-
fold higher steroid concentrations than were employed here for
11b-HSD2 labelling.
Several findings suggest that the affinity labelling procedure
described above occurs within the steroid binding pocket of the
active site. Firstly, the affinity labelling is NAD+-dependent, as is
11b-HSD2 activity. There are a few reports of cofactor-dependent
affinity labelling of other dehydrogenases. NAD+-dependent
lactate dehydrogenase is affinity labelled, in the presence of
NAD+, by bromopyruvate on the major catalytic residue
(histidine-195) [46]. Secondly, carbenoxolone, an 11b-HSD2
inhibitor, blocks labelling, as does a 1000-fold excess of unlabelled
corticosterone. Thirdly, the rank order of potency for gluco-
corticoid labelling correlateswith the substrate affinities of human
placental 11b-HSD2.
Finally, the glucocorticoid groups most likely to participate in
covalent photoaffinity labelling of 11b-HSD2 are the carbonyl
group at C-3 and the C-11 position itself. Labelling via the C-20
carbonyl appears less likely as it is expected to be less photo-
excitable, and covalent attachment of the C-20–C-21 grouping
(following the common C-17–C-20 cleavage) would not attach
any radioactivity, as the steroids are tritiated at C-1, -2, -6 and
-7 only. The C-3 carbonyl would be highly photoactivated to
produce both alkoxy radicals and reactive ketenes; both of these
would react relatively indiscriminately [47], potentially with
almost any closely approximated amino acid, but especially with
reactive cysteine, lysine, histidine or tyrosine residues. The
photoreactive state of C-11 is harder to anticipate, but is likely to
be greatly heightened in the active site where it will make the
transition to a C-11 carbonyl, a photoexcitable group in its own
right.
2-D electrophoresis
Fractions containing enzyme eluted from AMP–agarose were
affinity labelled with [$H]corticosterone and then subjected to
conventional 2-D electrophoresis (IEF plus SDS}PAGE). After
prolonged exposure, gel autoradiography remained negative.
Accordingly, NEPHGE gels were run. A strong signal, indicating
the presence of a single, affinity-labelled, protein spot of basic pI
(C 9.1) and apparent M
r
40000, was seen on autoradiography
(Figures 3a and 3b). It was notable that this was accompanied by
other proteins close to 40000-M
r
which were not affinity labelled.
NEPHGE conditions were optimized (Figure 3) to allow
preparative-scale gels with substantially increased yield and
reduced smearing of the affinity-labelled protein, which was
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Figure 3 Identification and preparative 2-D electrophoresis of homogeneous 11b-HSD2
Panels (a), (c) and (d) show silver-stained second-dimension gels of NEPHGE 2-D electrophoresis (running to basic pH as indicated). 11b-HSD2 (starred arrow) and two protein contaminants
(upward-pointing arrows) are indicated to assist orientation. Panel (b) shows an autoradiograph of a gel run in parallel, identical to the one in (a), but stained with Coomassie Blue and processed
for autoradiography. (a) and (b) NEPHGE analysis, with an even pH gradient (3–10 ; see the Experimental section) showing that the protein band(s) at 40000-Mr resolve into multiple protein spots,
of which 11b-HSD2 (clearly identified by autoradiography ; b) is one of the most abundant and basic in pI. (c) NEPHGE analysis with the pH gradient expanded at pH 6.5–8.0 to allow better
horizontal separation of 11b-HSD2 from nearby proteins at Mr 40000–43000. (d) Optimized preparative-scale 2-D electrophoresis for 11b-HSD2 with dodecyl-maltoside-based buffer (greatly
reducing streaking) and running the second dimension further to increase the vertical resolution. Note that the 10 mm scales refer to actual gels.
otherwise a major problem. The optimized procedure allowed
preparation of over 40 lg of homogeneous 11b-HSD2 protein,
which was blotted on to PVDF (Problott) membranes.
Several findings suggest that the 11b-HSD2 membrane en-
vironment has polar aspects. Thus moderate ionic strength
stimulates activity, the most hydrophobic lipid-like detergents
(e.g. Tween 20) are not the most useful for preserving 11b-HSD2
activity, and the 11b-HSD2 protein has a very high pI (" 9). The
very basic pI (9.1) is surprising. Proteins this basic are unusual,
often being ribosomal or associated with nucleic acid (chromatin
or RNA). Rarely are they intrinsic membrane proteins, and this
combination suggests interactions of 11b-HSD2 beyond NAD+
and steroids, perhaps with other membrane proteins or charged
lipid. Thus it may well be that interactions of this nature
(especially with phospholipid head groups) may be involved in
stabilizing the enzyme, as occurs with the related NAD+-
dependent short-chain alcohol dehydrogenase (SCAD) enzyme
3-hydroxybutyrate dehydrogenase [48]. We have not investigated
this further, as development of the affinity labelling technique
allowed purification of 11b-HSD2 to homogeneity, when activity
was not maintained.
Amino acid sequence
PVDF blots were stained with Amido Black and the 40000-M
r
target protein accurately excised. Sequencing of PVDF pieces
revealed that homogeneous 11b-HSD2 was N-terminally
blocked. This is unlikely to be an artifact of the purification as,
on sequencing, an amino acid signal was completely absent
(rather than just low), and we have obtained high-yield N-
terminal sequence from other proteins blotted from gels in the
same fashion. In situ tryptic digestion of approx. 30 lg of
11b-HSD2 protein produced multiple peptides and several of
these were sequenced, yielding in total over 100 residues of amino
acid sequence (Figure 4 and Table 1). Peptide G was blocked.
This was sub-digested with S. aureus V8 protease, yielding a
sequencable daughter peptide.
All peptide sequence obtained was unique, confirming 11b-
HSD2 as a novel protein. This is the first directly determined
11b-HSD2 peptide sequence from any source. Direct amino acid
sequencing provides information about amino acid order and
post-translational modification, and avoids some pitfalls of
cDNA-predicted amino acid sequencing, such as the use of rare
codons (e.g. selenocysteine). There is one potential N-linked
glycosylation site (NLS; peptide B) which in the native protein,
at least in human placenta, appears to be largely free of
glycosylation, as the amino acid sequence yield did not drop
across this asparagine residue. Peptide C contains a classical
SCAD motif (boxed in Table 1) indicating that 11b-HSD2
belongs to this enzyme superfamily. There was one clear ‘blank’
cycle in the middle of peptide C (cycle 15) ; it is possible that a
modified amino acid naturally occurs here. Further discussion of
the sequence is presented in the accompanying paper [30].
Overall purification procedure
Table 2 summarizes the steps in the purification procedure
described that allowed isolation of homogeneous 11b-HSD2
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Figure 4 Microbore HPLC profile of 11b-HSD2 tryptic digest
The solid line indicates the elution of peptide peaks (detected by A220 ; highest peaks
corresponding to C 500 pmol). The elution positions of trypsin and peaks from which the
peptide sequence was obtained (G obtained by V8 sub-digest) are indicated. The digest was
loaded on to the HPLC RP300 column equilibrated in solvent A (0.1% TFA in water) and
developed with a linear gradient (broken line) of 0–100% solvent B (0.08% TFA and 80%
acetonitrile in water) over 45 min at 200 ll/min.
protein from human placenta (" 16000-fold purification) and
direct determination of over 100 residues of its internal amino
acid sequence. In an accompanying paper [30], the amino acid
Table 1  11b-HSD2 peptide sequence
The amino acid and yield (in pmol) obtained on sequencing 11b-HSD2 peptides A–G are given by cycle number. Peptide B was sequenced twice (using a second sample from tryptic digestion of
purified 11b-HSD2). Cycle C(15) produced no residue signal. Cycles F(5), F(8), F(13) and C(6) produced two residues with similar yield, making assignment difficult. Cycle A(5) is definitely W, but
the yield imprecise. Note that the boxed sequence in peptide C is a classical SCAD motif, indicating the likely active site.
sequence derived has been used to clone a full-length 11b-HSD2
cDNA from a human placental library which, on transfection
into mammalian cells, expresses 11b-HSD2 activity and an
approx. 40000-M
r
protein which can be affinity labelled by the
method described above.
11b-HSD2 substrate binding and reaction mechanism
The primary objective of this work was to accomplish 11b-HSD2
purification. We feel that it also allows conclusions to be drawn
which may shed some light on the form of the enzyme’s active
site and kinetic mechanism. The striking specificity of the
photoaffinity labelling of 11b-HSD2 by corticosterone and
cortisol, in the presence of NAD+, demonstrates that 11b-HSD2
exhibits an unusually high, receptor-like, affinity for these
glucocorticoids, which may come close to that of GR or MR.
This finding underlies the physiological role of 11b-HSD2 in
binding, and inactivating, glucocorticoids with high avidity
before or in competition with GR and MR, so regulating
glucocorticoid access to receptors. 11b-HSD2 is probably not the
same as the C 45000-M
r
‘ low-affinity’ (K
d
C 100 nM) dexa-
methasone binding proteins identified in studies on male rat liver
[49], as it differs in localization, hierarchical order of binding
affinities and possibly Mg#+-dependence of binding (11b-HSD2
labelling occurs in EDTA-containing buffers). However, 11b-
HSD2 does resemble another, incompletely characterized,
receptor}binding protein for glucocorticoids: the type 3 corti-
costeroid (corticosterone) receptor [50,51]. Thus the rank order of
affinities determined in binding studies of these ‘ type 3 sites ’
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Table 2 Summary of purification of 11b-HSD2
Purification using 10 placentas yielded C 43 lg of C 16000-fold-purified 11b-HSD2. Affinity labelling of tracer amounts of 11b-HSD2 after AMP–agarose chromatography allowed a means
of assessing yields beyond this stage. 11b-HSD2 peptide recovery (following in situ tryptic digestion, elution from PVDF and microbore HPLC) was generally lower with increasing peptide
hydrophobicity (see Figure 4). Activity was measured as nmol/min per mg of protein.
Yield (%) Purification (fold)
Activity Recovery of
Purification step Protein Step Cumulative Step Cumulative (nmol/min per mg) radioactive tracer (%)
Homogenate 46.8 g – 100 – – 0.025 –
Subcellular fractionation 5.22 g 67 67 6 6 0.150 –
Solubilization 1.85 g 13 8.7 0.367 2.2 0.055 –
AMP–agarose 640 lg 36 3.15 1040 2290 57.3 –
2-D gel 43 lg 47 1.47 " 7 " 16000 – 100
Blot 30 lg 70 (1.05) – – – 70.2
Eluted peptides C 520 pmol (C 21 lg) 70* (0.75) – – – 49.8
Initial sequencing yield 445 pmol* 85 – – – – –
* Best yield.
[50,51] is consistent with the order of potency of the four steroids
used to affinity label 11b-HSD2 (Figure 2). ‘Type 3 sites ’ are
often regarded as cytosolic, which 11b-HSD2 is not. However,
the work originally defining them (in rat kidney) largely used
supernatants from centrifugation at 30000 g for 30 min, which is
very similar to the 25000 g}40 min fractionation that we have
used. Supernatant from such a spin will probably have approx.
95% of protein from the cytosol, but the remaining 5% will be
rich in protein from light microsomes and contain abundant 11b-
HSD2. Recent work on isolated renal cortical collecting duct
cells characterizes a similar binding site in whole cells (where
endogenous NAD+ may facilitate binding), which may be the
renal 11b-HSD2 isoform [51]. The characteristics of placental
11b-HSD2 are thus clearly similar to the ‘ type 3 sites ’ in these
reports. In the accompanying paper [30] this matter is addressed
further by examining the affinities of recombinant 11b-HSD2.
However, at present it is not settled whether ‘ type 3 sites ’ and
11b-HSD2 are the same entity.
The affinity chromatography data provide some clues to the
reaction order and nature of the active site of placental 11b-
HSD2. It is likely that 11b-HSD2 binding to N-6-5«-
AMP–agarose was via an interaction at the cofactor binding site.
5«-AMP is a ‘half molecule ’ of NAD+ (nicotinamide comprising
the remainder), and instances of N-6-5«-AMP affinity matrices
interacting with the cofactor site of NAD+-dependent dehydro-
genases are well documented [52]. We have shown the rank order
of potency by which free cofactors elute bound human placental
11b-HSD2 activity from N-6-5«-AMP–agarose to be NAD+ "
NADH" 5«-AMP(NADP+ (with 10-fold more 5«-AMP than
NAD+ required for elution) [27]. Thus for free cofactor the
binding site prefers NAD+, so appearing like a NAD+ cofactor
site as opposed to a 5«-AMP allosteric site. When the cofactor is
on the affinity matrix and not free, however, the rank order
changes to N-6-5«-AMP (yield over 35%)"C-8-NAD+(yield
C 2%) " N-6-NAD+ ¯ C-8-5«-AMP ¯ NADP+ (yield ¯ 0).
Clearly the attached spacer arms make a considerable difference,
sterically hindering NAD+ from binding more strongly than 5«-
AMP (as occurs with free cofactors). This may be a limitation of
the particular affinity matrix products used or simply be because
the larger size of NAD+ makes its binding more sensitive to steric
hindrance. A further possibility is that NAD+ may cause a
conformational change on binding (this quite frequently occurs
with dehydrogenases), whereas 5«-AMP, filling only a half site,
does not. Thus steric interference by the new conformation
prevents 11b-HSD2 binding to N-6-NAD+, but some limited
binding is then possible with C-8-NAD+ (which has the spacer
attachment rotated " 90° relative to N-6, both coming from the
5«-AMPhalf ofNAD+). 5«-AMP, causing no such conformational
change, binds well when N-6-linked, but not at all when C-8-
linked. The 5«-AMP affinity chromatography results suggest that
NAD+ can bind first to 11b-HSD2 (explaining both binding and
elution with NAD+). The NAD+-dependence of glucocorticoid
affinity labelling suggests that glucocorticoid cannot gain full
access to the steroid binding pocket unless NAD+ has bound
first. Affinity chromatography with dexamethasone–agarose was
unsuccessful under a range of elution conditions. The finding
that under similar conditions 11b-HSD2 is bound well by N-6-5«-
AMP agarose, but not at all by dexamethasone–agarose (though
dexamethasone is a substrate), may possibly also reflect a
‘cofactor first ’ binding order. By analogy with other de-
hydrogenases (e.g. lactate dehydrogenase [46]), these findings
collectively suggest that a compulsorily ordered ternary complex
mechanism may operate for 11b-HSD2, with NAD+ binding
first. Further studies of these matters will assist in mapping the
active site and in the design of drugs specifically to inhibit, or
possibly constitutively activate, 11b-HSD2.
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